Edoxaban is an oral, once-daily, direct factor Xa (FXa) inhibitor that has been evaluated for the prevention of stroke in patients with atrial fibrillation (AF) and for the treatment and prevention of venous thromboembolism (VTE) recurrence. Pharmacokinetic (PK) and pharmacodynamic (PD) modeling and logistic regression analyses were used to explore the clinical data from phase 1 and 2 studies to determine the relationship among PK exposure, PD response, and bleeding risk. Population PK/PD modeling was performed using plasma edoxaban concentration data from combined phase 1 and 2 studies and using intrinsic FXa data from a phase 2 AF study. A 2-compartment PK model adequately described the combined PK data, and a dynamic binding model characterized the dynamics of the intrinsic factor X activity (iFXa) data. Logistic regression analysis then identified the relationship between the iFXa and the observed bleeding risk. The more protracted suppression of FXa over the dosing interval for a 30-mg twice-daily dose compared with a 60-mg once-daily dose offers an explanation for the significantly higher bleeding rate at the former dose.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jcph.306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Back to basics: the coagulation pathway.
Blood Res
October 2024
Daisy Hill Hospital, 5 Hospital Road, Newry, BT35 8DR, UK.
The classic coagulation cascade model of intrinsic and extrinsic coagulation pathways, i.e. contact activation pathway and tissue factor pathway, has been widely modified.
View Article and Find Full Text PDFEstablishment of an Integrated Population Pharmacokinetic/Pharmacodynamics Model of Apixaban in Chinese Healthy Population Adjusting for Key Genetic Variants.
Curr Pharm Des
October 2024
Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.
Article Synopsis
- The study aims to enhance the understanding of how genetic and nongenetic factors influence the pharmacokinetics and pharmacodynamics (PK/PD) of apixaban to enable personalized medication prescriptions for future patients.* -
- Researchers created an integrated PK/PD model based on data from 181 healthy Chinese volunteers, analyzing various biological markers and genetic factors, with a total of 2877 observations used for the modeling process.* -
- The final PK model indicates key variables like clearance rate and absorption rate, while the PD model successfully simulates the effects of apixaban on relevant blood markers, supporting the idea that individual dosing can be tailored effectively.*
Saliva of persons with hemophilia A triggers coagulation via extrinsic tenase complexes.
Blood
December 2024
Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Article Synopsis
- Human saliva contains extracellular vesicles (EVs) that can activate blood coagulation through the presence of extrinsic tenase complexes, which include tissue factor and activated factor VII.
- Individuals with severe hemophilia A, who lack FVIII, have salivary EVs that can compensate for their condition by generating FXa, leading to infrequent oropharyngeal bleeding.
- In contrast, people with severe FVII deficiency lack these functional extrinsic tenase complexes in their saliva, resulting in more frequent oropharyngeal bleedings; however, adding recombinant FVIIa can restore coagulation potential in their saliva.
Structural, Biochemical Characterization and Molecular Mechanism of Cerastokunin: A New Kunitz-Type Peptide with Potential Inhibition of Thrombin, Factor Xa and Platelets.
Protein J
August 2024
Laboratory of Cellular and Molecular Biology, Faculty of Biological Sciences, USTHB, BP 32 El-Alia, Bab Ezzouar, Algiers, Algeria.
The current investigation focused on separating Cerastes cerastes venom to produce the first Kunitz-type peptide. Based on its anti-trypsin effect, Cerastokunin, a 7.75 kDa peptide, was purified until homogenity by three steps of chromatography.
View Article and Find Full Text PDFPreparation of an anticoagulant polyethersulfone membrane by immobilizing FXa inhibitors with a polydopamine coating.
J Biomater Sci Polym Ed
November 2024
Department of Nephrology, Xiangya Hospital of Central South University, Changsha, Hunan, China.
Article Synopsis
- Anticoagulation in patients undergoing hemodialysis poses a challenge due to protein adsorption and activation of the coagulation cascade, particularly involving activated Factor X (FXa).
- Researchers developed an anticoagulant dialysis membrane by coating it with polydopamine to graft FXa inhibitors (apixaban and rivaroxaban).
- Characterization showed that the modified membranes reduced protein adsorption and platelet activation, prolonged clotting times, and improved biocompatibility, indicating a promising strategy for enhancing antithrombotic properties in hemodialysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!